Literature DB >> 20213081

PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.

Jin Ho Kim, Doo Ho Choi, Dae Yeon Cho, Sei Hyun Ahn, Byung Ho Son, Bruce G Haffty.   

Abstract

PALB2 is a recently discovered breast cancer susceptibility gene, and mutations in the gene have been demonstrated to confer about twofold higher risk of breast cancer. Truncating mutations in PALB2 gene have been identified in varied populations. However, PALB2's significance to breast cancer has not been investigated in the Korean population. In this study, we evaluated the frequency of PALB2 1592delT and 229delT mutations in 300 Korean breast cancer patients diagnosed with either familial or early-onset breast cancer. All patients were confirmed negative for BRCA1 and BRCA2 mutations. Neither 1592delT nor 229delT mutations was found in any of the study cohort. Our results imply that these mutations are absent or rare in Korean patients who are negative for BRCA1 and BRCA2 mutations. We found no evidence to recommend screening for these mutations in the Korean population. However, PALB2 mutations have been demonstrated infrequent and inhomogeneous across investigated populations. Thus, screening the whole PALB2 gene for novel mutations is required to elucidate its significance in predisposition to breast cancer in Korean women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213081     DOI: 10.1007/s10549-010-0806-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Exome sequencing in a breast cancer family without BRCA mutation.

Authors:  Jae Myoung Noh; Jihun Kim; Dae Yeon Cho; Doo Ho Choi; Won Park; Seung Jae Huh
Journal:  Radiat Oncol J       Date:  2015-06-30

2.  PALB2: a novel inactivating mutation in a Italian breast cancer family.

Authors:  Cristina Balia; Elisa Sensi; Grazia Lombardi; Manuela Roncella; Generoso Bevilacqua; Maria Adelaide Caligo
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

3.  Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation.

Authors:  Haeyoung Kim; Dae-Yeon Cho; Doo Ho Choi; Gee Hue Jung; Inkyung Shin; Won Park; Seung Jae Huh; Sung-Won Kim; Sue K Park; Jong Won Lee; Seok Jin Nam; Jeong Eon Lee; Won Ho Gil; Seok Won Kim
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  PALB2 mutation in a woman with bilateral breast cancer: A case report.

Authors:  Hiroshi Nakagomi; Yosuke Hirotsu; Kenichiro Okimoto; Ikuko Sakamoto; Kenji Amemiya; Satoko Nakagomi; Takeo Kubota; Hitoshi Mochizuki; Masao Omata
Journal:  Mol Clin Oncol       Date:  2017-03-09

5.  Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.

Authors:  Hiroshi Nakagomi; Ikuko Sakamoto; Yosuke Hirotsu; Kenji Amemiya; Hitoshi Mochiduki; Masao Omata
Journal:  Int J Clin Oncol       Date:  2015-09-28       Impact factor: 3.402

6.  Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.

Authors:  Haeyoung Kim; Dae-Yeon Cho; Doo Ho Choi; Gee Hue Jung; Inkyung Shin; Won Park; Seung Jae Huh; Seok Jin Nam; Jeong Eon Lee; Won Ho Gil; Seok Won Kim
Journal:  Cancer Res Treat       Date:  2016-01-19       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.